| Return |
Patient Evidence Summary
Doctor, I need treatment for a superficial blood clot (SVT). Can I take a blood thinner pill instead of an injection?
For some people with superficial vein thrombosis, blood thinner pills such as rivaroxaban may be an alternative to fondaparinux injections. The available studies did not show clear differences in clot problems or bleeding, but the evidence is limited.
Not all patients with superficial vein thrombosis need treatment with blood thinners.
Always discuss with your healthcare provider before making any changes to your medications.
Study highlights
In patients receiving short-term treatment for standard-risk superficial vein thrombosis, DOACs (mostly rivaroxaban) had similarly low rates of bleeding compared with fondaparinux and showed no clear important differences in preventing the clot from getting bigger, coming back, or moving to deeper veins or the lungs.
Understanding the problem
Superficial vein thrombosis (SVT) is a type of blood clot that forms in the veins just under the skin. While these are lower-risk clots, they can still cause pain and, in some cases, move to more dangerous locations, such as the deeper veins, causing deep vein thrombosis (DVT), or the lungs, causing pulmonary embolism (PE).
In some cases, doctors will use blood thinners to treat SVTs. In these cases, the blood thinner is often used for shorter lengths of time and at lower doses than treatments for more serious blood clots, such as pulmonary embolism.
One standard treatment for SVTs is with under-the-skin injections of a medication called fondaparinux for 45 days.
The researchers wanted to study whether DOACs, which are a convenient pill-based therapy, were as safe and effective as fondaparinux in the treatment of SVT.
To answer this question, the authors performed a systematic review with meta-analysis. A meta-analysis is a statistical method used to get more accurate information about a treatment by combining the results of studies together. This is similar to judging a sports team based on how they perform over an entire season, rather than just one game.
Who?
The authors looked at 6 studies of patients with large SVTs, defined as 5 cm or longer.
Patients with higher-risk SVTs, such as clots less than 3 cm from the deep veins, and patients at higher risk of bleeding, such as those with severe kidney disease, were excluded from the studies.
In total, 2040 adult patients were included.
Patients either received a DOAC, fondaparinux, low-molecular-weight-heparin, or no anticoagulation (placebo).
What?
The authors compared the safety (bleeding risk) and effectiveness in treating SVTs of the different blood thinner treatments.
| Outcomes | Risk with DOAC vs fondaparinux | Interpretation |
|---|---|---|
| Development of PE or DVT | DOACs and fondaparinux showed no clear difference. These events were uncommon with both treatments.* | DOACs appeared similar to fondaparinux for preventing more serious blood clots, but the evidence is limited. |
| Extension or recurrence of SVT | DOACs and fondaparinux showed no clear difference. These events were uncommon with both treatments.* | DOACs appeared similar to fondaparinux for preventing the clot from extending or recurring, but the evidence is limited. |
| Bleeding | DOACs and fondaparinux showed no clear important difference in bleeding. Bleeding was extremely uncommon with both treatments.* | DOACs did not appear to cause more bleeding than fondaparinux, but the evidence is limited. |
*Because few people had these events, the results are uncertain. The studies did not show a clear difference between DOACs and fondaparinux, but more research could change these conclusions.
This Evidence Summary is based on the following article:
Boccatonda A, Brighenti A, Simion C, et al. Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost. 2026 Jan 27. doi: 10.1055/a-2788-3034. PubMed
Hannah Ramsay, MD, PhD
Hannah is a second-year Internal Medicine Resident at the University of Toronto. Before residency, she completed an MD/PhD at Queen’s University, studying nanomaterials and how they can be used in the treatment of cancer. Her interests include hematology as well as translational and equity research in this space.
Zachary Liederman, MD
Zach recently graduated from the University of Toronto Hematology Residency Program and is currently pursuing additional training as both a CanVECTOR fellow and as the Alexandra Yeo Fellow in Thrombosis and Hemostasis at the University of Toronto. He is in the process of completing a Master’s degree in medical education and looks forward to contributing to existing and new teaching projects centered around thromboembolism.
Published: Tuesday, May 19, 2026
Please note that the information contained herein is not to be interpreted as an alternative to medical advice from a professional healthcare provider. If you have any questions about any medical matter, you should consult your professional healthcare providers, and should never delay seeking medical advice, disregard medical advice or discontinue medication based on information provided here.
|
This Evidence Summary was printed from the CLOT+ website on 2026/05/31. To view other Evidence Summaries or to register to receive email notifications about new Evidence Summaries, please visit us at https://plus.mcmaster.ca/ClotPlus/Articles/EvidenceSummaries |
|
, McMaster University